EMEA-001214-PIP06-20

Key facts

Invented name
Fasenra
Active substance
benralizumab
Therapeutic area
Dermatology
Decision number
P/0314/2020
PIP number
EMEA-001214-PIP06-20
Pharmaceutical form(s)
  • Age-appropriate dosage form for parenteral use
  • Solution for injection
Condition(s) / indication(s)
Treatment of bullous pemphigoid
Route(s) of administration
Subcutaneous use
Contact for public enquiries
AstraZeneca AB

E-mail: paediatrics@astrazeneca.com
Tel.  +46 855326000
 

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating